Navigation Links
Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon

Third Eye(TM) Retroscope(TM) Improved Polyp Detection by Thirteen Percent

SAN DIEGO, May 21 /PRNewswire/ -- At the Digestive Disease Week conference in San Diego (DDW 2008), world-renowned gastroenterologist Jerome D. Waye, MD presented clinical results from a multi-institutional study which evaluated the efficacy of the Third Eye(TM) Retroscope(TM), a new device that improves the ability of physicians to visualize abnormalities in the colon.

The study showed that the Third Eye Retroscope, when used in combination with a standard colonoscope, detects a significantly higher number of adenomas and other polyps than the colonoscope alone. The Third Eye Retroscope has been cleared for use in the U.S. by the Food and Drug Administration (FDA).

"It is quite an ingenious device," said Dr. Waye. "The technology behind it is amazing."

Colorectal cancer is the second greatest cause of cancer death in the U.S. However, most cancers of the lower gastrointestinal (GI) tract can be completely cured if they are detected early. Even more cases can be completely prevented if pre-cancerous polyps can be removed before they become malignant.

Principal Investigator Dr. Waye, of Mount Sinai Hospital in New York, presented the study results yesterday afternoon in front of physicians and other industry professionals during the conference, being held at the San Diego Convention Center. The multi-center study has evaluated 214 patients to date at eight sites across the U.S. During the study, patients were examined using a Third Eye Retroscope in combination with a standard colonoscope. The abstract of the study by Dr. Waye and his co-authors was accepted for publication by the DDW review panel of the American Society for Gastrointestinal Endoscopy (ASGE). Dr. Waye was also invited to present the abstract during this week's annual conference.

"Colonoscopy is currently considered the best method for colorectal cancer screening. However, it is well-established from previous research that lesions may be missed, especially on the proximal aspect of haustral folds and flexures or behind the ileocecal valve," said Dr. Waye.

Used during colonoscopy, the Third Eye Retroscope is an auxiliary imaging device that provides retrograde illumination and visualization of the colon for diagnostic purposes. Developed by Avantis Medical Systems, Inc. of Sunnyvale, Calif., this innovative new endoscopic device is passed through the instrument channel of a standard colonoscope until it extends beyond the tip of the colonoscope. As it emerges, the device automatically turns around 180 degrees to provide a continuous retrograde view while the colonoscope is being withdrawn.

Colonoscopy is widely regarded as the "gold standard" for detection of abnormalities in the colon. However, previous research has revealed that 12-24% of polyps and a significant number of cancers can be missed during colonoscopy, especially if they lie behind folds in the colon wall. [1],[2], [3] This new device is designed to solve this problem by allowing the physician to view the opposite side of those folds during the procedure.

The study (which is still active) has found that, in combination with a standard colonoscope, the Third Eye Retroscope detected 13.3% additional polyps, and 12.4% additional adenomas, compared with the colonoscope alone. Polyps detected with the Third Eye were comparable in size to those seen with the colonoscope.

"Our investigators are finding that the Third Eye Retroscope is a promising new technology for improving visualization during colonoscopy," continued Dr. Waye. "During the study, the Third Eye revealed areas that are often hidden from the forward-viewing colonoscope, and it allowed a significant increase in detection of adenomas and other polyps."

In the 214 patients studied to date, 203 polyps were identified with the standard colonoscope. With the Third Eye Retroscope, an additional 27 polyps were detected, an increase of 13.3%. With the standard colonoscope, 105 adenomas were found; and with the Third Eye Retroscope, an additional 13 adenomas were detected, an increase of 12.4%. Mean size for polyps found by the colonoscope alone was 0.49 cm, and mean size for polyps found by the Third Eye Retroscope was virtually identical, at 0.47 cm.

In 21 patients (9.8%), at least one additional polyp was found with the use of the Third Eye Retroscope, and in seven patients (3.3%), the polyp detected with the Third Eye Retroscope was the only one found.

Dr. Waye is clinical professor of medicine and chief of the G.I. endoscopy unit at the Mount Sinai Medical Center in New York City.

Known for introducing the concept of colonoscopy without fluoroscopy by defining endoscopic landmarks, Dr. Waye has authored seven books, innumerable abstracts, and has published almost two hundred scientific papers in peer- reviewed journals.

He is president-elect and has been treasurer of OMED, the international organization for digestive endoscopy. In 1980, he was president of the ASGE and in 1982 became president of the American College of Gastroenterology (ACG). He has also received the highest honors awarded by these organizations: the Schindler Award (from the ASGE) and the Founder's Award (from the ACG).

He is organizing the International Congress of Endoscopy, to be held in Los Angeles, Calif. in 2011.

About the Study

Study sites included Mayo Clinic, Scottsdale, AZ; M.D. Anderson Cancer Center-University of Texas, Houston, TX; Indiana University, Indianapolis, IN; University of Michigan, Ann Arbor, MI; Camino Medical Group & El Camino Hospital, Mountain View, CA; and Washington University, St. Louis, MO. Although the original published abstract reported on the initial 100 patients in the study, Dr. Waye's DDW presentation reported on the study's initial 214 patients.

About DDW

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American Association for the Study of Liver Diseases and the Society for Surgery of the Alimentary Tract, DDW takes place May 17 - 22, 2008, at the San Diego Convention Center. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit

About the Technology

The Third Eye Retroscope is designed to complement, not to replace, standard colonoscopes. Therefore it does not alter existing procedural infrastructure or referral patterns, and does not require major outlay from medical facilities for capital equipment. The device can be used with most of the adult colonoscopes currently produced by the leading manufacturers, as well as some pediatric colonoscopes.

The "chip-on-catheter" platform for the Third Eye Retroscope is also the basis for a number of other products that Avantis is developing for use in gastroenterology, and in other medical and surgical specialties. Like the Third Eye Retroscope, most of these innovative devices are designed to be disposable, which eliminates the need for sterilization and the risk of contamination.

About Avantis

Avantis Medical Systems, Inc. is a medical device company founded to develop and manufacture catheter-based endoscopic devices. Based in Sunnyvale, Calif., the Company's initial focus is on devices for use in detecting pre- cancerous lesions and other abnormalities of the gastrointestinal (GI) tract.

The Avantis team has many decades of experience in the medical device industry, and focuses on developing solutions for problems, hazards and inconveniences associated with traditional technologies. The Company has developed an extensive portfolio of patents covering innovative devices based on the convergent technologies of micro-chips and reinforced catheters.

[1] Pickhardt, P.J.; Nugent, P.A.; Mysliwiec, P.A.; Choi, J.R.; Schindler, W.R. Location of adenomas missed by optical colonoscopy. Annals of Internal Medicine 141(5):352-360, 2004.

[2] Pabby, A.; Schoen, R.E.; Weissfeld, J.L.; Burt, R.; Kikendall, J.W.; Lance, P.; Shike, M.; Lanza, E.; Schatzkin, A. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointestinal Endoscopy 61(3):385-391, 2005.

[3] Rex, D.K.; Cutler, C.S.; Lemmel, G.T.; Rahmani, E.Y.; Clark, D.W.; Helper, D.J.; Lehman, G.A.; Mark, D.G. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 112(1):24-28, 1997.

SOURCE Avantis Medical Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Israeli study finds obstructive sleep apnea is health factor from day 1
2. Study finds that recalled Aqua Dots did contain poisonous chemical
3. Study reveals link among childhood allergies, asthma symptoms, and early life exposure to cats
4. Study analyzed SYMBICORT in children with persistent asthma
5. New patient satisfaction study with budesonide/formoterol combination therapy
6. Study: Doctors not always sure when to treat BP in people with diabetes
7. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
8. Study: Doctors Not Always Sure When to Treat Blood Pressure in People With Diabetes
9. JAMA publication features study on depression and head and neck cancer
10. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
11. With age comes a sense of peace and calm, population research center study shows
Post Your Comments:
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)... PHILADELPHIA , Oct. 2, 2017 Halo Labs announces ... particle analysis system called the HORIZON at MIBio 2017 in ... analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented ... use of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: